Biogen Idec Doubling Multiple Sclerosis Sales Force For Antegren Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will have almost 200 MS sales reps by the time Antegren is expected to launch in early 2005. Partner Elan also will contribute specialty reps for the hospital outpatient setting. Biogen Idec's pre-launch efforts are focusing on reimbursement and neurologists' capacities for I.V. administration.
You may also be interested in...
Antegren Launch Will Be “Very Aggressive,” Biogen Idec Says
The company expects marketing expenses to increase into next year to support the launch, including dissemination of two-year Phase III data after mid-2005. First Antegren patients will likely be those who have failed other therapies, CEO Mullen says
Antegren Launch Will Be “Very Aggressive,” Biogen Idec Says
The company expects marketing expenses to increase into next year to support the launch, including dissemination of two-year Phase III data after mid-2005. First Antegren patients will likely be those who have failed other therapies, CEO Mullen says
Elan Dismisses Merger Speculation
Elan said it is not in discussions with Biogen Idec concerning a potential merger or business combination of the two companies